 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 303
|
|
-
Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin
(16 May 2008)
Oncolytics Biotech Inc. announced that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using ......
-
Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea
(22 Apr 2008)
SMT D002 suppresses sebum levels by 90% in repeat-dose trial
Summit Corporation plc announced a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhoea (excessive sebum production), a primary cause of acne. The study was conducted in 18 ......
-
Scientists discover the travel patterns of seasonal flu
(22 Apr 2008)
Findings may lead to improved flu vaccines
Outbreaks of the most common type of influenza virus, A (H3N2), are seeded by viruses that originate in East and Southeast Asia and migrate around the world, new research has found. This discovery may help to further improve flu vaccines and ......
-
BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients
(14 Apr 2008)
Novel Combination Therapy Shown to be Well-Tolerated and to Reduce the Apnoea-Hypopnoea Index in OSA Patients
BTG reports additional details from its positive clinical proof of concept study of BGC20-0166 in subjects with mild to severe obstructive sleep apnoea. BGC20-0166 is a novel combination of two marketed serotonin modulating drugs being ......
-
Antisoma announces start of phase III lung cancer trial of ASA404
(14 Apr 2008)
Initiation triggers USD 25 million milestone payment from Novartis
Antisoma plc announced that its partner Novartis has started the pivotal phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for ......
-
ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology, focusing on Gene & Genome Synthesis and Assembly
(04 Apr 2008)
ITI Life Sciences issued a Call for Expressions of Interest from organisations or individuals with expertise in Synthetic Biology techniques that could be applied to Gene & Genome Synthesis and Assembly. ITI Life Sciences' is seeking to ......
-
Popular apple variety harbors unusual cell growth
(27 Mar 2008)
A UK scientist has discovered clumps of previously-unreported callus hairs growing in the flesh of mature apples of Fuji and closely-related varieties, which may have storage implications for commercial growers. "To find out something new about ......
-
Cenix BioScience and CellCentric Sign Framework Research Agreement for RNAi-Based Target Validation.
(26 Mar 2008)
Cenix BioScience GmbH announced that it has signed a framework research agreement to support CellCentric Ltd through cell-based validation of novel therapeutic drug targets for oncology. Cenix will apply its expertise in combining high ......
-
Oxford BioMedica develops strategic development plan with the commercialisation of TroVax
(20 Mar 2008)
Oxfordshire Bioscience Network (OBN), organisers of the forth coming Bio Trinity 2008 conference, has confirmed Peter Nolan, SVP Commercial Development at Oxford BioMedica as a lead speaker on this years programme. Mr Nolan will discuss the ......
-
Predictive genetic test for bowel cancer treatment is introduced in the UK
(20 Mar 2008)
Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test
Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients ......
|
|
|
Top